Success Metrics

Active Trials
9(47%)

Phase Distribution

Ph early_phase_1
1
5%
Ph not_applicable
2
11%
Ph phase_2
1
5%
Ph phase_1
13
68%

Phase Distribution

14

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution17 total trials
Early Phase 1First-in-human
1(5.9%)
Phase 1Safety & dosage
13(76.5%)
Phase 2Efficacy & side effects
1(5.9%)
N/ANon-phased studies
2(11.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

9

trials recruiting

Total Trials

19

all time

Status Distribution
Active(9)
Other(10)

Detailed Status

unknown10
Recruiting8
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
9
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (5.9%)
Phase 113 (76.5%)
Phase 21 (5.9%)
N/A2 (11.8%)

Trials by Status

recruiting842%
active_not_recruiting15%
unknown1053%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT06429150Phase 1

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Recruiting
NCT06481241Not Applicable

Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL

Recruiting
NCT06481228Not Applicable

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

Recruiting
NCT03434769Phase 1

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

Active Not Recruiting
NCT04008524

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Unknown
NCT06698484Phase 2

To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

Recruiting
NCT06352281Phase 1

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

Recruiting
NCT05779917Phase 1

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

Recruiting
NCT05420493Phase 1

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Unknown
NCT03240328Phase 1

The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function

Recruiting
NCT04863066Phase 1

Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection

Unknown
NCT04790747Phase 1

Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions

Unknown
NCT04766840Phase 1

Donor-derived CAR-T Cells in the Treatment of AML Patients

Unknown
NCT02186860Phase 1

Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia

Unknown
NCT04532203Early Phase 1

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Recruiting
NCT04287309

CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS

Unknown
NCT03881774Phase 1

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Unknown
NCT03525782Phase 1

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Unknown
NCT02980315Phase 1

A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application

Unknown

All 19 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
19